David Westenberg
Stock Analyst at Piper Sandler
(4.30)
# 273
Out of 5,182 analysts
188
Total ratings
51.46%
Success rate
17.76%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GRAL GRAIL | Maintains: Neutral | $54 → $56 | $63.77 | -12.18% | 2 | May 6, 2026 | |
| FLGT Fulgent Genetics | Reiterates: Neutral | $30 → $15 | $15.09 | -0.60% | 11 | May 5, 2026 | |
| CAI Caris Life Sciences | Initiates: Neutral | $21 | $19.80 | +6.06% | 1 | Apr 10, 2026 | |
| WGS GeneDx Holdings | Maintains: Overweight | $160 → $130 | $39.00 | +233.33% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $130 | $90.36 | +43.87% | 11 | Feb 24, 2026 | |
| NEO NeoGenomics | Maintains: Overweight | $12 → $13 | $9.04 | +43.81% | 11 | Feb 24, 2026 | |
| LH Labcorp Holdings | Maintains: Neutral | $270 → $300 | $256.47 | +16.98% | 5 | Feb 24, 2026 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $775 → $750 | $572.01 | +31.12% | 12 | Feb 9, 2026 | |
| ILMN Illumina | Maintains: Overweight | $195 → $170 | $139.39 | +21.96% | 17 | Feb 9, 2026 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $24 → $30 | $24.14 | +24.28% | 11 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $135 | $87.06 | +55.07% | 16 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6.5 → $10 | $9.17 | +9.11% | 14 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $85.50 | +75.44% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $19 | $22.31 | -14.84% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $80 | $50.22 | +59.31% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $2 | $1.69 | +18.34% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $230 | $216.20 | +6.38% | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7.5 | $4.91 | +52.91% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $200 | $189.64 | +5.46% | 8 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $14.81 | +35.04% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $11.03 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $25.24 | - | 1 | Nov 21, 2017 |
GRAIL
May 6, 2026
Maintains: Neutral
Price Target: $54 → $56
Current: $63.77
Upside: -12.18%
Fulgent Genetics
May 5, 2026
Reiterates: Neutral
Price Target: $30 → $15
Current: $15.09
Upside: -0.60%
Caris Life Sciences
Apr 10, 2026
Initiates: Neutral
Price Target: $21
Current: $19.80
Upside: +6.06%
GeneDx Holdings
Feb 24, 2026
Maintains: Overweight
Price Target: $160 → $130
Current: $39.00
Upside: +233.33%
Guardant Health
Feb 24, 2026
Maintains: Overweight
Price Target: $120 → $130
Current: $90.36
Upside: +43.87%
NeoGenomics
Feb 24, 2026
Maintains: Overweight
Price Target: $12 → $13
Current: $9.04
Upside: +43.81%
Labcorp Holdings
Feb 24, 2026
Maintains: Neutral
Price Target: $270 → $300
Current: $256.47
Upside: +16.98%
IDEXX Laboratories
Feb 9, 2026
Maintains: Neutral
Price Target: $775 → $750
Current: $572.01
Upside: +31.12%
Illumina
Feb 9, 2026
Maintains: Overweight
Price Target: $195 → $170
Current: $139.39
Upside: +21.96%
Elanco Animal Health
Jan 22, 2026
Upgrades: Overweight
Price Target: $24 → $30
Current: $24.14
Upside: +24.28%
Jan 22, 2026
Downgrades: Neutral
Price Target: $190 → $135
Current: $87.06
Upside: +55.07%
Jan 12, 2026
Reiterates: Neutral
Price Target: $6.5 → $10
Current: $9.17
Upside: +9.11%
Dec 1, 2025
Initiates: Overweight
Price Target: $150
Current: $85.50
Upside: +75.44%
Nov 11, 2025
Maintains: Neutral
Price Target: $15 → $19
Current: $22.31
Upside: -14.84%
Nov 11, 2025
Maintains: Neutral
Price Target: $105 → $80
Current: $50.22
Upside: +59.31%
Nov 11, 2025
Maintains: Neutral
Price Target: $1.5 → $2
Current: $1.69
Upside: +18.34%
Nov 11, 2025
Maintains: Overweight
Price Target: $220 → $230
Current: $216.20
Upside: +6.38%
Nov 11, 2025
Maintains: Overweight
Price Target: $8 → $7.5
Current: $4.91
Upside: +52.91%
Oct 27, 2025
Maintains: Neutral
Price Target: $190 → $200
Current: $189.64
Upside: +5.46%
Oct 15, 2025
Maintains: Overweight
Price Target: $15 → $20
Current: $14.81
Upside: +35.04%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $11.03
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $25.24
Upside: -